Physician profile
Peter J Lydon
NPI 1801874532
$15,109.84
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,426 · 2020: $1,955 · 2021: $5,310 · 2022: $3,643 · 2023: $1,710 · 2024: $66.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,710 · Food and Beverage: $66.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,710.00 |
| Food and Beverage | $66.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linvatec Corporation | $4,400.00 | 2020-2022 | |
| Medtronic, INC. | $3,250.00 | 2021 | |
| Conmed Corporation | $2,421.52 | 2020-2022 | |
| Covidien Lp | $1,769.65 | 2019-2020 | |
| Olympus Medical Systems Corporation | $1,710.00 | 2023 | Oes Choledochofiberscope |
| Intuitive Surgical, INC. | $1,308.74 | 2019-2022 | |
| Ethicon US, LLC | $153.52 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $37.31 | 2024 | Myrisk |
| W. L. Gore & Associates, INC. | $29.04 | 2024 | Gore Enform Preperitoneal Biomaterial |
| Innocoll Pharmaceuticals Limited | $17.76 | 2021 | |
| Smith+Nephew, INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lydon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.